Dr. Girard Discusses PALOMA-2 at 2024 American Society of Clinical Oncology Annual Meeting

Nicolas Girard, MD, PhD, of Institut Curie, discusses PALOMA-2 results at the 2024 American Society of Clinical Oncology Annual Meeting. The phase 2 trial evaluated subcutaneous amivantamab and lazertinib as a first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer.

“Amivantamab historically is delivered intravenously…here in PALOMA-2, we are looking at a subcutaneous injection of amivantamab,” Dr. Girard explained. “It’s a different formulation for this drug, which is delivered at 1600 milligrams with the same dosing schedule.”

He spoke about the results of the study presented during the annual meeting and what has been observed so far in patients receiving first-line subcutaneous amivantamab and lazertinib.

“We have response rate results that are in line with those reported in MARIPOSA. It is above 75%. The vast majority of patients will show a response on the target lesions,” Dr. Girard said. “We do not yet have the survival outcomes in this study, but the median duration of response was not reached at the time of follow-up for this cohort of patients.”

There are multiple benefits associated with using the subcutaneous formulation of amivantamab rather than the intravenous version, he said.

“What is very interesting with subcutaneous amivantamab is not only the fact that it’s easier for the patient and the hospital organization, [but] it is also associated with a lower risk of adverse events [(AEs)],” he said.

For example, there is a “high risk” of administration-related reactions that occur with the amivantamab intravenous formulation,” he said.

“[Reactions occur in] 60% of the patients, historically,” Dr. Girard explained. “The studies with the subcutaneous formulation, it’s 15%. We are reducing the risk for these administration-related reactions.”

Dr. Girard spoke about the next steps, explaining that “MARIPOSA is being implemented as a new standard of care for the first-line treatment of patients.” Overall, the PALOMA-2 study is showing that the subcutaneous formulation of amivantamab provides “better quality of life” for patients and a “reduction in the risk of [AEs],” he said.